Predict your next investment

MiraDx company logo
HEALTHCARE | Disease Diagnosis
miradx.com

See what CB Insights has to offer

Founded Year

2008

Stage

Series A | Alive

Total Raised

$1M

Last Raised

$1M | 11 yrs ago

About MiraDx

Mira Dx is a genomics company dedicated to the development and commercialization of novel microRNA-based diagnostic tests.

MiraDx Headquarter Location

11600 Wilshire Blvd., Suite 410

Los Angeles, California, 90025,

United States

424-387-8100

Latest MiraDx News

FDA OKs emergency use of new COVID-19 test with OraSure collection device

Sep 4, 2020

Sep. 3, 2020 4:44 PM ET The FDA has approved emergency use authorization of an in-house SARS-CoV-2 molecular test developed at MiraDx. The nod includes OraSure's (NASDAQ: OSUR ) ORAcollect-RNA device for the collection of oropharyngeal samples. OSUR says this is the fifth COVID-19 test using one of its collect devices approved for emergency use in the U.S. Shares down 1% after-hours.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MiraDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MiraDx is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

MiraDx Patents

MiraDx has filed 4 patents.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/11/2015

5/7/2019

Synthetic estrogens, Estranes, Selective estrogen receptor modulators, Phenols, Hormonal antineoplastic drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/11/2015

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/7/2019

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Synthetic estrogens, Estranes, Selective estrogen receptor modulators, Phenols, Hormonal antineoplastic drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

MiraDx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MiraDx Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.